OneMedNet
ONMD on Nasdaq. OneMedNet sells clinical imaging data and patient records to life science partners. Market value $317m.
Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-25.79 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$4.70 a share, 30% above its 1-year low
Over the past year the price has ranged from $3.61 to $23.00.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | ||||
| Revenue | $1m | $1m | $643,000 | $1m |
| Operating margin | ||||
| Operating margin | -669.1% | -671.2% | -1493.8% | -711.3% |
| Debt to equity | ||||
| Debt to equity | n/a | n/a | n/a | n/a |
| Shares outstanding | ||||
| Shares outstanding | 0.03bn | 0.03bn | 0.05bn | 0.01bn |
Health checks
- Free cash flow positive0 of 4 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsSlow, 5.6% a year
- Buying back its own sharesYes, 81% fewer since 2022
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $1 million last quarter, up 478% on a year ago.
- A loss of $3 million, compared with a loss of $741,000 a year ago.
- It loses 440 cents on each $1 of sales, compared with 1883 cents a year earlier.
- 17% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $26,000 |
| March 2025 | $137,000 |
| June 2025 | $155,000 |
| September 2025 | $177,000 |
| December 2025 | $891,000 |
| March 2026 | $96,000 |
| June 2026 | $292,000 |
| September 2026 | $1m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$2m |
| March 2025 | -$2m |
| June 2025 | $3m |
| September 2025 | -$741,000 |
| December 2025 | -$3m |
| March 2026 | -$2m |
| June 2026 | -$2m |
| September 2026 | -$3m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 March 2026
- Next quarterly (estimated, 10-Q)
- 15 February 2027
Who owns it
None of the long-term investors we follow own it. 22 funds in all.
Largest holders overall
- Savant Capital$5mNew
- Vanguard Capital Management$819,221Added
- Geode Capital Management$237,709
- Vanguard Fiduciary Trust$97,909
- BlackRock$86,017Added
- State Street$82,974
- Discovery Capital Management$79,811
- PNC Financial Services Group$73,469Added
- OpenArc Corporate Advisory$69,261Added
- Northern Trust$33,300Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
No one has reported a stake above 5% since December 2024.
- TD SECURITIES (USA) LLCPassive investorSold down below 5%Since 30 September 2026
- Off the Chain LPPassive investorSold down below 5%Since 30 September 2026
- DISCOVERY CAPITAL MANAGEMENT, LLCPassive investorSold down below 5%Since 30 September 2025
- COWEN AND COMPANY, LLCPassive investorSold down below 5%Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
TD SECURITIES (USA) LLC Passive investor | Sold down below 5% | 30 September 2026 | |
Off the Chain LP Passive investor | Sold down below 5% | 30 September 2026 | |
DISCOVERY CAPITAL MANAGEMENT, LLC Passive investor | Sold down below 5% | 30 September 2025 | |
COWEN AND COMPANY, LLC Passive investor | Sold down below 5% | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $4m of shares on the open market. 2 sold $103,052.
- Yu JeffreyChief Medical Officer, DirectorBought
- Date
- 9 October 2026
- Shares
- 45,126
- Price
- $5.54
- Value
- $249,998
- Kosasa ThomasDirectorBought
- Date
- 7 October 2026
- Shares
- 129,758
- Price
- $5.78
- Value
- $750,001
- Green AaronChief Executive Officer, DirectorSold
- Date
- 24 September 2026
- Shares
- 1,667
- Price
- $6.48
- Value
- $10,802
- Green AaronChief Executive Officer, DirectorSold
- Date
- 22 September 2026
- Shares
- 5,000
- Price
- $7.39
- Value
- $36,960
- Golden Robert LawrenceChief Financial Officer, DirectorSold
- Date
- 21 September 2026
- Shares
- 3,000
- Price
- $6.63
- Value
- $19,890
- Golden Robert LawrenceChief Financial Officer, DirectorSold
- Date
- 15 September 2026
- Shares
- 3,000
- Price
- $6.30
- Value
- $18,900
- Golden Robert LawrenceChief Financial Officer, DirectorSold
- Date
- 14 September 2026
- Shares
- 2,500
- Price
- $6.60
- Value
- $16,500
- Yu JeffreyChief Medical Officer, DirectorBought
- Date
- 10 September 2026
- Shares
- 142,857
- Price
- $0.63
- Value
- $90,000
- Kosasa ThomasDirectorBought
- Date
- 30 July 2026
- Shares
- 1,449,275
- Price
- $0.69
- Value
- $1,000,000
- Green AaronChief Executive Officer, DirectorBought
- Date
- 23 June 2026
- Shares
- 36,650
- Price
- $0.57
- Value
- $20,891
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 9 October 2026 | Yu Jeffrey Chief Medical Officer, Director | Bought | 45,126 | $5.54 | $249,998 |
| 7 October 2026 | Kosasa Thomas Director | Bought | 129,758 | $5.78 | $750,001 |
| 24 September 2026 | Green Aaron Chief Executive Officer, Director | Sold | 1,667 | $6.48 | $10,802 |
| 22 September 2026 | Green Aaron Chief Executive Officer, Director | Sold | 5,000 | $7.39 | $36,960 |
| 21 September 2026 | Golden Robert Lawrence Chief Financial Officer, Director | Sold | 3,000 | $6.63 | $19,890 |
| 15 September 2026 | Golden Robert Lawrence Chief Financial Officer, Director | Sold | 3,000 | $6.30 | $18,900 |
| 14 September 2026 | Golden Robert Lawrence Chief Financial Officer, Director | Sold | 2,500 | $6.60 | $16,500 |
| 10 September 2026 | Yu Jeffrey Chief Medical Officer, Director | Bought | 142,857 | $0.63 | $90,000 |
| 30 July 2026 | Kosasa Thomas Director | Bought | 1,449,275 | $0.69 | $1,000,000 |
| 23 June 2026 | Green Aaron Chief Executive Officer, Director | Bought | 36,650 | $0.57 | $20,891 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
2 serious warning signs in OneMedNet’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 8 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.”
Show the full paragraph
Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.
From the 10-Q filed 16 November 2026, Part I, Item 2. Management's Discussion and Analysis. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.
From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
An insider just bought shares with their own money. The deep dive asks why.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.